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Angiogenesis plays an important role in the pathogenesis of idiopathic pulmonary
fibrosis. Pulmonary fibrosis occurs also in many diseases, such as other types of
interstitial pneumonias or drug-induced pulmonary fibrosis. The aim of the study was
to examine the effect of sera from patients with various types of pulmonary fibrosis
on angiogenesis induced by human mononuclear cells (MNC) in relation to lung
functions. The study population consisted of 32 patients with idiopathic pulmonary
fibrosis (IPF), 11 patients with drug-induced pulmonary fibrosis (DIPF), 6 with
cryptogenic organizing pneumonia (COP), and 20 healthy volunteers. An animal
model of leukocyte-induced angiogenesis assay was used as an angiogenic test.
Spirometry, whole-body plethysmography, static lung compliance (Cst), and
diffusing capacity of the lung for CO (DLco) were performed in all patients. Sera
from IPF and COP patients significantly stimulated angiogenic activity of MNC,
compared with sera from healthy donors and from DIPF patients (P<0.001).
However, sera from healthy donors and DIPF significantly stimulated angiogenic
activity of MNC compared with the control group with PBS (P<0.001). In all groups,
a decrease in the mean value of Cst and DLco was observed, but no significant
correlation between VC, FEV1, DLco, Cst, and angiogenic activity of sera fromexamined patients was found. Sera obtained from patients with pulmonary fibrosis
constitute a source of mediators modulating angiogenesis, but the pattern of reaction
is different in various diseases. The strongest reaction is observed in IPF and the
weakest one in DIPF. The angiogenic activity of sera did not correlate with the
pulmonary function of patients with pulmonary fibrosis.
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INTRODUCTION
Idiopathic interstitial pneumonias are a heterogeneous group of diffuse
parenchymal lung diseases (1). Idiopathic pulmonary fibrosis is the most
common idiopathic interstitial pneumonia. This is a progressive lung disease of
unknown etiology characterized by fibroblast proliferation and extracellular
matrix remodeling, which results in irreversible distortion of the lung’s
architecture (1). International multidisciplinary consensus classification of the
idiopathic interstitial pneumonias distinguishes six other forms, such as acute
interstitial pneumonia, nonspecific interstitial pneumonia (NSIP), cryptogenic
organizing pneumonia, respiratory bronchiolitis - associated interstitial lung
disease and lymphoid interstitial pneumonia (2). Cryptogenic organizing
pneumonia (COP) is a fibrous pulmonary disorder in which a new fibromyxoid
connective tissue is formed in distal air spaces. In COP this tissue is subject to a
complete reversal, but in usual interstitial pneumonia (UIP/IPF) it participates in
the remodeling of pulmonary interstitium (3). Pulmonary fibrosis is also observed
in the course of interstitial lung diseases (ILD) with known etiology, such as drug-
induced pulmonary fibrosis, radiotherapy, pneumoconiosis, extrinsic allergic
alveolitis, and in disorders of unknown etiology, such as sarcoidosis and collagen
vascular disease - associated interstitial pneumonia (4-6). Although the
pathogenetic mechanisms and etiology in ILD are diverse, they all can lead to an
identical end-stage fibrotic pulmonary scar. The drug-induced chronic lung
damage does not resemble IPF (7). Pulmonary function tests including vital
capacity (VC), Cst, and DLco reflect a degree of pulmonary fibrosis (8). Aberrant
vascular remodeling is a central hallmark of the development and progression of
IPF (9-11), but the role of angiogenesis in various fibrotic pulmonary diseases
remains to be determined.
The aim of the study was to evaluate the effect of sera from various types of
pulmonary fibrosis on angiogenesis induced by human mononuclear cells in
relation to pulmonary function.
MATERIAL AND METHODS
Patients
The protocol was approved by a local Ethical Committee and all subjects gave informed
consent. The study population consisted of 49 patients with pulmonary fibrosis. According to their
final diagnosis, patients were divided into 3 groups: 32 patients with IPF, 11 patients with DIPF, and
6 with COP. Diagnoses of IPF, COP, and DIPF were based on clinical, radiological, and
histopathological findings, according to the ATS/ERS standards (1-2). The population of IPF
patients consisted of 14 women and 18 men aged 37-73 (60.7 ±11.5 years), 23 of whom had never
smoked tobacco. The population group of DIPF patients consisted of 4 women and 7 men aged 39-
77 (63.2 ±11.2 years), 10 of whom had never smoked tobacco. Fibrosis was induced in 6 patients
by amiodarone and in one each by nitrofurantoin, colchicine, methotrexate, cyclophosphamide, and
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gold salts. The population group of COP patients consisted of 3 women and 3 men aged 44-68 (59.3
±9.1 years), 5 of whom had never smoked tobacco. Sera from 20 healthy, never smoking volunteers
were used as a control. All samples were stored at -80°C.
Lung function tests
In all cases, spirometry, whole body plethysmography, static lung compliance, and single-breath
diffusing capacity of the lung for carbon monoxide tests were performed by the experienced staff
according to ERS standards (12), using MasterLab Jaeger equipment (Hochberg, Germany).
Reference values according to ERS guidelines were applied (12).
Angiogenesis test
The study was performed in 8-10 week old inbred female Balb/c mice. Mononuclear cells were
isolated from the peripheral blood samples of healthy volunteers using a Histopaque 1077 (Sigma
Chemicals, St. Louis, MA) gradient technique according to the Boyum method (13), with our own
modification (14). As an angiogenic test, a leukocyte-induced angiogenesis assay (LIA) in animal
model according to Sidky and Auerbach was used (15), with modification described previously (14).
Briefly, 6 samples of 0.05 ml volume containing 2.5 x 105 MNC were injected intradermally into
mice anesthetized with 3.6% chloral hydrate (Fig. 1). Three mice were used for each examined
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Fig. 1. Scheme of experiments in which angiogenic activity of human mononuclear cells (MNC)
was evaluated after their preincubation with patients or healthy volunteers’ sera and with PBS
without sera as a control.
patient. After 72 h the mice were sacrificed with a lethal dose of Morbital and their skin was 
dissected from the underling tissue. All newly formed blood vessels were identified on the inner skin
surface and counted by dissection microscope, at magnification 6x, in 1/3 of the central area of the
microscopic field. The identification was based on the criteria proposed by Sidky and Auerbach (15).
New blood vessels connected with the injection sites (visible by trypan blue) and contrasting with the
background vasculature by virtue of their tortuosity and divarication were counted.
Statistical analysis
For standardization of the value of the angiogenesis test, the results were expressed as an
angiogenesis index (AI):
The mean number of new blood vessels created after injection of MNC 
preincubated with serum of patients (or PBS)
AI = _______________________________________________________________________________________________________
The mean number of new blood vessels created after injection of MNC
preincubated with serum of healthy donors
The data were presented as means ±SD and P<0.05 was regarded as statistical significance.
Student’s t and Pearson’s tests were used for statistical analysis (Statistica 6 for Windows).
RESULTS
Sera from IPF and COP patients significantly stimulated angiogenesis
compared with those from healthy subjects (Fig. 2A). The mean number of new
vessels formed after injection of MNC preincubated with sera from IPF patients
was 16.2 ±0.9 and was significantly higher than the 15.4 ±0.9 after injection of
MNC preincubated with COP patients (P<0.05). Sera from IPF and COP
significantly stimulated angiogenesis compared with those from DIPF patients
(P<0.001). However, compared with PBS, sera from healthy donors also exerted
a stimulating effect on angiogenesis (P<0.001). The mean number of vessels after
the injection of MNC preincubated with sera from a healthy control (13.7 ±0.7)
did not statistically differ from the number of vessels created after the injection of
MNC preincubated with sera from DIPF patients (13.2 ±1.3). Sera from DIPF
patients significantly stimulated angiogenesis compared with PBS (P<0.05). The
results expressed as an angiogenesis index are presented in Fig. 2B. The highest
angiogenesis index was in the group of patients with IPF (1.2 ±0.1) and the lowest
one was in the group of patients with DIPF (1.0 ±0.1) (P<0.001).
The mean value of VC in all groups of patients with pulmonary fibrosis was
within a normal range and no significant differences were observed between the
examined groups (Fig. 3A). The mean DLco value decreased in the group of
patients with IPF (59.0 ±17.6%) and DIPF (57.0 ±19.8). The mean DLco in the
group of COP patients was higher (75.0 ±22.7%), which was not significant in
relation to the IPF patient (P=0.067) (Fig. 3B). In all groups, static compliance
was lower than the predictive value (Fig. 3C). The lowest mean value of Cst was
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observed in the IPF group (44.0 ±15.9%) and the highest one in the COP group
(64.0 ±28.8%). The difference was significant (P<0.02). No significant
correlation between VC, FEV1, DLco, Cst, and the number of new vessels or
angiogenesis index was found (Fig. 4).
DISCUSSION
Angiogenesis is characterized by neoformation of blood vessels in many
physiological and pathological processes, such as the growth of malignant solid
tumors, chronic inflammation, and a formation of inflammatory granulation
tissue during wound healing (16). IPF is a typical interstitial pulmonary disease
characterized by chronic inflammation. Recently, pulmonary fibrosis has been
proposed to result from abnormal wound healing in the lung in response to injury
to the alveolar epithelium (17). Parallels have been drawn between the biology of
IPF and cancer (18). The existence of neovascularization in IPF was originally
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Fig. 2. A - Number of new vessels formed after injection of MNC preincubated in sera from IPF
(n=32), DIPF (n=11), COP patients (n=6), and from healthy donors (n=20) or PBS (n=20); B -
Angiogenesis index after preincubation of MNC in sera from IPF, DIPF, and COP patients
compared with the angiogenesis index for PBS. The mean values are indicated by horizontal bars,
significant differences between the groups are indicated.
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Fig. 3. Distribution of lung function results for patients with pulmonary fibrosis: A - VC, B - DLco,
and C - Cst. The mean values are indicated by horizontal bars, significant differences between the
groups are indicated.
Fig. 4. Correlations between VC (A), FEV1 (B), Cst (C), and DLco (D), and the number of new
vessels (r - Pearson’s coefficient).
identified by Turner-Warwick in 1963 (19), but only Keane et al (20, 21) have
demonstrated an increased angiogenic activity in the lung tissue of IPF and
experimental drug-induced pulmonary fibrosis. Our present results demonstrated
significant differences between serum angiogenic activity in patients with IPF
and DIPF, but similar functional disturbances. Patients with DIPF presented
radiological and functional fibrotic changes without continuous progression
typical of IPF. The animals with intensive angiogenesis in experimental
bleomycin-induced pulmonary fibrosis presented an active phase of the process
induced by the drug. In all our cases of DIPF, the harmful treatment was stopped
after diagnosis and patients were examined in an inactive phase of the disease.
Perhaps, it explains why serum angiogenic activity in patients with DIPF was
similar to the activity of sera from healthy controls.
Koyama et al (22) and Meyer et al (23) have reported a decreased expression
of a vascular endothelial cell growth factor (VEGF) in IPF. Renzoni et al (24), after
examination of interstitial vascularity in fibrosing alveolitis, have suggested that
angiogenesis may occur in earlier stages of the development of pulmonary fibrosis,
because of the reduction in total vascular area and vascular density in IPF patients.
Burdick et al (25) have demonstrated that angiogenic activity in the lungs of
patients with IPF was significantly decreased. However, Simler et al (26) have
described a correlation between the serum VEGF level and HRCT fibrosis score,
and a negative relation to the change in FVC after 6 months. In our study, no
correlation was found between serum angiogenic activity and functional changes
connected with pulmonary fibrosis such as VC, FEV1 Cst, and DLco. No
differences in serum angiogenic activity were observed between patients with
advanced and moderate functional pulmonary changes. The results of the present
study indicate that serum angiogenic activity does not depend on the functional or
radiological changes, but relates to the phase and activity of the fibrotic process.
Angiogenesis also participates in the pathogenesis of COP. Angiogenic
chemokines and factors such as CXCR3, VEGF, and bFGF are highly expressed
in lesions in COP (27, 28). Presented results showed high angiogenic activity of
serum from patients with COP. Previously it has been reported that capillarization
is less frequent in fibroblastic foci of IPF than in the intraluminal fibromyxoid
lesions COP (3). In the present study, the angiogenic activity of sera from IPF
patients was higher than that of sera from COP patients.
Recently, Tachihara et al (29) have demonstrated in NSIP and IPF patients a
decrease in expression of VEGF mRNA in the alveolar septa, which was
associated with a reduction in the number of capillary tubes via endothelial cell
apoptosis, and which possibly results in alveolar remodeling. Nakayama et al (30)
have observed that serum levels of ENA-78 and BALF levels of IP10 in NSIP
patients were significantly higher than in patients with IPF and in controls.
Therefore, further research on neovascularization in pulmonary fibrosis seems
necessary. The fundamental question remains: ‘Are there too many or too few
new vessels in pulmonary fibrosis?’
777
We conclude that sera of patients with pulmonary fibrosis constitute the source
of mediators modulating angiogenesis, but the pattern of reaction is different in
various diseases. The strongest angiogenic reaction is observed in IPF and the
weakest one in DIPF. The angiogenic activity of sera did not correlate with
pulmonary function of patients with pulmonary fibrosis.
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